Year: 2022
Type: article
Abstract: The wide range in presentation, treatment response and outcome of diffuse large B-cell lymphoma (DLBCL) reflects a large underlying biological heterogeneity [ 1 ]. Various molecular DNA-, RNA- and protein-based subtyping approaches have been proposed over time, but failed to sufficiently capture its biological heterogeneity in a clinically sufficient manner, precluding major clinical consequences [ 2 , 3 , 4 , 5 ]. The most recent DNA-based subtyping studies as independently proposed by the Dana Farber Cancer Institute (DFCI) and the National Cancer Institute (NCI) are a major step forward [ 6 , 7 ]. These subtypes are based on DNA-mutation, genome-wide copy number aberration (CNAs), and translocation information. Despite different bioinformatic approaches, the resulting 5- to 7 subtypes largely recognize similar DLCBL pathogenicities and starts to offer a clinically impactful refinement at a level sufficient to serve as a basis for exploration of personalized and targeted treatment in the coming years. Its clinical potential already paid off with the recent finding that benefit from the BTK inhibitor ibrutinib plus R-CHOP is highly specifically associated with two of the genetic subtypes [ 8 ]. To enable consistent trial designs and meaningful comparisons between studies, we consider it pivotal to harmonize the currently available DNA-subtyping knowledge into a single classification, preferably widely applicable in diagnostic routine. In this perspective we investigate harmonization opportunities and suggest potential avenues from a bioinformatics point of view.
Source: Leukemia
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,590
Funder: KWF Kankerbestrijding
Awards: G1451685634, G270329785, G2703844096
OpenAlex ID: W4290072647
